488 related articles for article (PubMed ID: 8954168)
1. Active specific immunotherapy of pulmonary metastasis with vaccinia melanoma oncolysate prepared from granulocyte/macrophage-colony-stimulating-factor-gene-encoded vaccinia virus.
Ju DW; Cao X; Acres B
J Cancer Res Clin Oncol; 1996; 122(12):716-22. PubMed ID: 8954168
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic effect of vaccinia virus secreting granulocyte-macrophage colony-stimulating factor on pulmonary metastatic melanoma].
Ju D; Cao X; Ma S
Zhonghua Zhong Liu Za Zhi; 1996 May; 18(3):165-8. PubMed ID: 9387245
[TBL] [Abstract][Full Text] [Related]
3. Oncolytic and immunologic cancer therapy with GM-CSF-armed vaccinia virus of Tian Tan strain Guang9.
Deng L; Fan J; Guo M; Huang B
Cancer Lett; 2016 Mar; 372(2):251-7. PubMed ID: 26803055
[TBL] [Abstract][Full Text] [Related]
4. Recombinant vaccinia virus expressing cytokine GM-CSF as tumor vaccine.
Chatterjee SK; Qin H; Manna S; Tripathi PK
Anticancer Res; 1999; 19(4B):2869-73. PubMed ID: 10652566
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral injection of GM-CSF gene encoded recombinant vaccinia virus elicits potent antitumor response in a mixture melanoma model.
Ju DW; Cao X; Acres B
Cancer Gene Ther; 1997; 4(2):139-44. PubMed ID: 9080123
[TBL] [Abstract][Full Text] [Related]
6. Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF.
Qin H; Chatterjee SK
Hum Gene Ther; 1996 Oct; 7(15):1853-60. PubMed ID: 8894677
[TBL] [Abstract][Full Text] [Related]
7. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells.
Cao X; Zhang W; Wang J; Zhang M; Huang X; Hamada H; Chen W
Immunology; 1999 Aug; 97(4):616-25. PubMed ID: 10457215
[TBL] [Abstract][Full Text] [Related]
8. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation.
van Elsas A; Hurwitz AA; Allison JP
J Exp Med; 1999 Aug; 190(3):355-66. PubMed ID: 10430624
[TBL] [Abstract][Full Text] [Related]
9. Immunization with a syngeneic tumor infected with recombinant vaccinia virus expressing granulocyte-macrophage colony-stimulating factor (GM-CSF) induces tumor regression and long-lasting systemic immunity.
McLaughlin JP; Abrams S; Kantor J; Dobrzanski MJ; Greenbaum J; Schlom J; Greiner JW
J Immunother; 1997 Nov; 20(6):449-59. PubMed ID: 9409450
[TBL] [Abstract][Full Text] [Related]
10. Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy.
Stagg J; Wu JH; Bouganim N; Galipeau J
Cancer Res; 2004 Dec; 64(24):8795-9. PubMed ID: 15604233
[TBL] [Abstract][Full Text] [Related]
11. Enhancing therapy of B16F10 melanoma efficacy through tumor vaccine expressing GPI-anchored IL-21 and secreting GM-CSF in mouse model.
Zhao F; Dou J; He XF; Wang J; Chu L; Hu W; Yu F; Hu K; Wu Y; Gu N
Vaccine; 2010 Apr; 28(16):2846-52. PubMed ID: 20153795
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines.
Klein C; Bueler H; Mulligan RC
J Exp Med; 2000 May; 191(10):1699-708. PubMed ID: 10811863
[TBL] [Abstract][Full Text] [Related]
13. CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma.
Sandler AD; Chihara H; Kobayashi G; Zhu X; Miller MA; Scott DL; Krieg AM
Cancer Res; 2003 Jan; 63(2):394-9. PubMed ID: 12543793
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effect of a vaccinia colon oncolysate prepared with interleukin-2-gene encoded vaccinia virus studied in a syngeneic CC-36 murine colon hepatic metastasis model.
Sivanandham M; Scoggin SD; Tanaka N; Wallack MK
Cancer Immunol Immunother; 1994 Apr; 38(4):259-64. PubMed ID: 8168121
[TBL] [Abstract][Full Text] [Related]
15. Granulocyte-macrophage colony-stimulating factor gene-transduced tumor cells combined with tumor-derived gp96 inhibit tumor growth in mice.
Kojima T; Yamazaki K; Tamura Y; Ogura S; Tani K; Konishi J; Shinagawa N; Kinoshita I; Hizawa N; Yamaguchi E; Dosaka-Akita H; Nishimura M
Hum Gene Ther; 2003 May; 14(8):715-28. PubMed ID: 12804136
[TBL] [Abstract][Full Text] [Related]
16. Novel membrane-bound GM-CSF vaccines for the treatment of cancer: generation and evaluation of mbGM-CSF mouse B16F10 melanoma cell vaccine.
Yei S; Bartholomew RM; Pezzoli P; Gutierrez A; Gouveia E; Bassett D; Soo Hoo W; Carlo DJ
Gene Ther; 2002 Oct; 9(19):1302-11. PubMed ID: 12224013
[TBL] [Abstract][Full Text] [Related]
17. Comparative antitumor effect among GM-CSF, IL-12 and GM-CSF+IL-12 genetically modified tumor cell vaccines.
Miguel A; Herrero MJ; Sendra L; Botella R; Algás R; Sánchez M; Aliño SF
Cancer Gene Ther; 2013 Oct; 20(10):576-81. PubMed ID: 23969885
[TBL] [Abstract][Full Text] [Related]
18. Intensified antitumor immunity by a cancer vaccine that produces granulocyte-macrophage colony-stimulating factor plus interleukin 4.
Wakimoto H; Abe J; Tsunoda R; Aoyagi M; Hirakawa K; Hamada H
Cancer Res; 1996 Apr; 56(8):1828-33. PubMed ID: 8620500
[TBL] [Abstract][Full Text] [Related]
19. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
[TBL] [Abstract][Full Text] [Related]
20. Macrophage colony-stimulating factor complementary DNA: a candidate for gene therapy in metastatic melanoma.
Walsh P; Dorner A; Duke RC; Su LJ; Glode LM
J Natl Cancer Inst; 1995 Jun; 87(11):809-16. PubMed ID: 7791230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
